Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CRBN | Q96SW2 | 17/20 | 0.57 |
| ▸ | IKZF2 | Q9UKS7 | 3/20 | 0.52 |
| ▸ | CSNK1A1 | P48729 | 3/20 | 0.51 |
| ▸ | GSPT1 | P15170 | 2/20 | 0.47 |
| ▸ | IKZF1 | Q13422 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1413771 | 0.91 | IKZF2 (0.55) | CRBNIKZF2CSNK1A1GSPT1 | |
| SCHEMBL1413390 | 0.90 | CRBN (0.59) | CRBNIKZF2CSNK1A1GSPT1IKZF1 | |
| SCHEMBL1413504 | 0.88 | CRBN (0.59) | CRBNIKZF2CSNK1A1GSPT1IKZF1 | |
| SCHEMBL1413559 | 0.88 | IKZF2 (0.55) | CRBNIKZF2CSNK1A1GSPT1 | |
| SCHEMBL1413692 | 0.87 | CRBN (0.62) | CRBNIKZF2CSNK1A1GSPT1IKZF1 | |
| SCHEMBL1413640 | 0.86 | CRBN (0.57) | CRBNIKZF2CSNK1A1GSPT1IKZF1 | |
| SCHEMBL1413409 | 0.86 | CRBN (0.63) | CRBNCSNK1A1GSPT1IKZF1 | |
| SCHEMBL476959 | 0.86 | CRBN (0.57) | CRBNIKZF2CSNK1A1GSPT1IKZF1 | |
| SCHEMBL1413597 | 0.86 | CRBN (0.60) | CRBNCSNK1A1 | |
| SCHEMBL20760056 | 0.86 | CRBN (0.72) | CRBNIKZF2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220056287-A1 | ACTIVE ENERGY RAY-CURABLE FLEXOGRAPHIC PRINTING INK COMPOSITION | SAKATA INX CORPORATION (JP) | 2022-02-24 | — | — | US | disclosed |
| US-20220056286-A1 | ACTIVE ENERGY RAY-CURABLE COMPOSITION | SAKATA INX CORPORATION (JP) | 2022-02-24 | — | — | US | disclosed |
| EP-3904395-A1 | ACTIVE ENERGY RAY-CURABLE COMPOSITION | Sakata INX Corporation (JP) | 2021-11-03 | — | — | EP | disclosed |
| EP-3901225-A1 | ACTIVE ENERGY RAY-CURABLE FLEXOGRAPHIC PRINTING INK COMPOSITION | Sakata INX Corporation (JP) | 2021-10-27 | — | — | EP | disclosed |
| WO-2020130016-A1 | ACTIVE ENERGY RAY-CURABLE FLEXOGRAPHIC PRINTING INK COMPOSITION | サカタインクス株式会社 | 2020-06-25 | — | — | WO | disclosed |
| EP-3327013-B1 | 5-SUBSTITUTED ISOINDOLINE COMPOUNDS | CELGENE CORP (US) | 2019-04-24 | — | — | EP | disclosed |
| EP-3327013-A1 | 5-SUBSTITUTED ISOINDOLINE COMPOUNDS | Celgene Corporation (US) | 2018-05-30 | — | — | EP | disclosed |
| EP-3061758-B1 | 5-SUBSTITUTED ISOINDOLINE COMPOUNDS | CELGENE CORP (US) | 2018-01-31 | — | — | EP | disclosed |
| US-9801868-B2 | 5-substituted isoindoline compounds | CELGENE CORPORATION (US) | 2017-10-31 | — | — | US | disclosed |
| US-20160346264-A1 | 5-SUBSTITUTED ISOINDOLINE COMPOUNDS | CELGENE CORPORATION | 2016-12-01 | — | — | US | disclosed |
| EP-2749559-B1 | 5-substituted isoindoline compounds | CELGENE CORP (US) | 2016-04-27 | — | — | EP | disclosed |
| EP-2291365-B1 | 5-SUBSTITUTED ISOINDOLINE COMPOUNDS | CELGENE CORP (US) | 2015-03-11 | — | — | EP | disclosed |
| US-20150005303-A1 | 5-SUBSTITUTED ISOINDOLINE COMPOUNDS | CELGENE CORPORATION | 2015-01-01 | — | — | US | disclosed |
| US-8877780-B2 | 5-substituted isoindoline compounds | CELGENE CORPORATION (US) | 2014-11-04 | — | — | US | disclosed |
| EP-2749559-A1 | 5-substituted isoindoline compounds | CELGENE CORPORATION (US) | 2014-07-02 | — | — | EP | disclosed |
| EP-2057143-B1 | 5-SUBSTITUTED ISOINDOLINE COMPOUNDS | CELGENE CORP (US) | 2013-07-24 | — | — | EP | disclosed |
| EP-2291365-A1 | 5-SUBSTITUTED ISOINDOLINE COMPOUNDS | CELGENE CORPORATION (US) | 2011-03-09 | — | — | EP | disclosed |
| WO-2009145899-A1 | 5-SUBSTITUTED ISOINDOLINE COMPOUNDS | CELGENE CORPORATION (US) | 2009-12-03 | — | — | WO | disclosed |
| US-20090142297-A1 | 5-SUBSTITUTED ISOINDOLINE COMPOUNDS | CELGENE CORPORATION | 2009-06-04 | — | — | US | disclosed |
| US-20090099278-A1 | Acrylated Polyaminoamide (II) | COGNIS IP MANAGEMENT GMBH (DE) | 2009-04-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160346264-A1 | 5-SUBSTITUTED ISOINDOLINE COMPOUNDS | CYP3A5, CYP3A7, CYP3A4 | CRBN 4610/4885IKZF2 3972/4885CSNK1A1 554/4885 |
| US-20150005303-A1 | 5-SUBSTITUTED ISOINDOLINE COMPOUNDS | CYP3A5, CYP3A7, CYP3A4 | CRBN 4610/4885IKZF2 3972/4885CSNK1A1 554/4885 |
| US-20090142297-A1 | 5-SUBSTITUTED ISOINDOLINE COMPOUNDS | CYP3A5, CYP3A7, CYP3A4 | CRBN 4610/4885IKZF2 3972/4885CSNK1A1 554/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.